Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy

Background. The wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be of...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Corrado Pelaia, Claudia Crimi, Santi Nolasco, Giovanna Elisiana Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi, Claudia Gagliani, Vincenzo Patella, Girolamo Pelaia, Giuseppe Valenti, Nunzio Crimi
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2021-12-01
סדרה:	Biomedicines
נושאים:	severe asthma allergy eosinophils omalizumab benralizumab switching
גישה מקוונת:	https://www.mdpi.com/2227-9059/9/12/1822
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!